Literature DB >> 25380734

Change in population prevalences of human papillomavirus after initiation of vaccination: the high-throughput HPV monitoring study.

Anna Söderlund-Strand1, Ingrid Uhnoo2, Joakim Dillner3.   

Abstract

BACKGROUND: Organized human papillomavirus (HPV) vaccination was introduced in Sweden in 2012. On-demand vaccination was in effect from 2006 to 2011. We followed the HPV prevalences in Southern Sweden from 2008 to 2013.
METHODS: Consecutive, anonymized samples from the Chlamydia trachomatis screening were analyzed for HPV DNA for two low-risk types and 14 high-risk types using PCR with genotyping using mass spectrometry. We analyzed 44,146 samples in 2008, 5,224 in 2012, and 5,815 in 2013.
RESULTS: Registry-determined HPV vaccination coverages of the population in Southern Sweden increased mainly among 13- to 22-year-old women. Most analyzed samples contained genital swabs from women and the HPV6 prevalence in these samples decreased from 7.0% in 2008 to 4.2% in 2013 [-40.0%; P < 0.0005 (χ(2) test)]. HPV16 decreased from 14.9% to 8.7% (-41.6%; P < 0.0005) and HPV18 decreased from 7.9% to 4.3% (-45.6%; P < 0.0005) among 13- to 22-year-old women. There were only small changes in vaccination coverage among 23- to 40-year-old women. In this age group, HPV18 decreased marginally (-19.6%; P = 0.04) and there were no significant changes for HPV6 or HPV16. Two nonvaccine HPV types (HPV52 and HPV56) were increased among 13- to 22-year-old women, both in 2012 and 2013.
CONCLUSIONS: A major reduction of HPV6, 16, and 18 prevalences is seen in the age groups with a concomitant increase in HPV vaccination coverage. The minor changes seen for nonvaccine types will require further investigation. IMPACT: Monitoring of type-specific HPV prevalences may detect early effects of HPV vaccination. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25380734     DOI: 10.1158/1055-9965.EPI-14-0687

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  14 in total

Review 1.  Human Papillomavirus Laboratory Testing: the Changing Paradigm.

Authors:  Eileen M Burd
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

2.  Non-Vaccine-Type Human Papillomavirus Prevalence After Vaccine Introduction: No Evidence for Type Replacement but Evidence for Cross-Protection.

Authors:  Mónica Saccucci; Eduardo L Franco; Lili Ding; David I Bernstein; Darron Brown; Jessica A Kahn
Journal:  Sex Transm Dis       Date:  2018-04       Impact factor: 2.830

3.  Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.

Authors:  P Goggin; C Sauvageau; V Gilca; F Defay; G Lambert; S Mathieu-C; J Guenoun; E Comète; F Coutlée
Journal:  Hum Vaccin Immunother       Date:  2017-12-13       Impact factor: 3.452

4.  Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.

Authors:  Mélanie Drolet; Élodie Bénard; Norma Pérez; Marc Brisson
Journal:  Lancet       Date:  2019-06-26       Impact factor: 79.321

5.  Differences between vaccinated and unvaccinated women explain increase in non-vaccine-type human papillomavirus in unvaccinated women after vaccine introduction.

Authors:  Lili Ding; Lea E Widdice; Jessica A Kahn
Journal:  Vaccine       Date:  2017-11-21       Impact factor: 3.641

6.  Substantial Decline in Vaccine-Type Human Papillomavirus (HPV) Among Vaccinated Young Women During the First 8 Years After HPV Vaccine Introduction in a Community.

Authors:  Jessica A Kahn; Lea E Widdice; Lili Ding; Bin Huang; Darron R Brown; Eduardo L Franco; David I Bernstein
Journal:  Clin Infect Dis       Date:  2016-09-20       Impact factor: 9.079

7.  Validation of a standardized extraction method for formalin-fixed paraffin-embedded tissue samples.

Authors:  Camilla Lagheden; Carina Eklund; Sara Nordqvist Kleppe; Elizabeth R Unger; Joakim Dillner; Karin Sundström
Journal:  J Clin Virol       Date:  2016-04-27       Impact factor: 3.168

8.  Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study.

Authors:  David Mesher; Kavita Panwar; Sara L Thomas; Simon Beddows; Kate Soldan
Journal:  BMJ Open       Date:  2016-02-11       Impact factor: 2.692

9.  Infections and cancer: the "fifty shades of immunity" hypothesis.

Authors:  Camille Jacqueline; Aurélie Tasiemski; Gabriele Sorci; Beata Ujvari; Fatima Maachi; Dorothée Missé; François Renaud; Paul Ewald; Frédéric Thomas; Benjamin Roche
Journal:  BMC Cancer       Date:  2017-04-12       Impact factor: 4.430

10.  Cancer: A disease at the crossroads of trade-offs.

Authors:  Camille Jacqueline; Peter A Biro; Christa Beckmann; Anders Pape Moller; François Renaud; Gabriele Sorci; Aurélie Tasiemski; Beata Ujvari; Frédéric Thomas
Journal:  Evol Appl       Date:  2016-12-26       Impact factor: 5.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.